Pancreatic ductal adenocarcinoma remains one of the deadliest cancer subtypes. Preclinical evidence has suggested that PARP inhibitors are synergistic with topoisomerase inhibitors, and clinical effectiveness of the PARP inhibitor veliparib plus modified FOLFIRI (mFOLFIRI; no 5-FU bolus) was observed. Chiorean and colleagues conducted a randomized phase II clinical trial assessing second-line veliparib and mFOLFIRI versus FOLFIRI in patients with metastatic pancreatic adenocarcinoma. An interim futility analysis revealed that veliparib plus mFOLFIRI was unlikely to improve prognosis but was more likely to cause grade 3/4 toxicity. Interestingly, trends were detected indicating that FOLFIRI treatment may improve PFS and OS in patients with alterations in homologous recombination DNA damage repair. Further clinical study is necessary to determine if this subgroup of patients will benefit from FOLFIRI treatment.

Marginal zone lymphoma (MZL) is a rare non-Hodgkin lymphoma reliant on B-cell receptor signaling. Opat and colleagues conducted a phase II clinical trial to assess...

You do not currently have access to this content.